What are the indications for clopidogrel as a mono- and combined therapy?
Clopidogrel is indicated for the secondary prevention for atherosclerotic events in patients intolerant of aspirin [1-3 ]. NICE states: “For a person who is intolerant of low-dose aspirin and who either has experienced an OVE or has symptomatic PAD, clopidogrel alone is prescribed within its licensed indications.” [3] The SPC for Plavix notes: “Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease” [4] In combination with aspirin, clopidogrel is licensed for non-ST-segment-elevation acute coronary syndrome (ACS). “In patients with non-ST-segment-elevation acute coronary syndrome (ACS) who are at moderate to high risk of MI or death, clopidogrel 75mg daily should be considered in combination with low-dose aspirin (75mg daily) for up to 12 months following the most recent acute event. Thereafter, treatment should revert to low-dose aspirin alone. This is t
